Article
Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data.
Familial cancer - 5 May 2025
Lanjouw Lieke, Kramer Claire J H, Elst Arja Ter, de Bock Geertruida H, Gaarenstroom Katja N, Yigit Refika, Berger Lieke P V, van Asperen Christi J, Commandeur-Jan Sabrina Z, van der Hall Dimas M X, Jalving Mathilde, Kagie Marjolein J, van der Stoep Nienke, van Wezel Tom, Mourits Marian J E, Bosse Tjalling, Bart Joost
Abstract excerpt
Identification of somatic and germline BRCA1/2 pathogenic variants in epithelial ovarian cancer (EOC) patients is essential for determining poly-(ADP-ribose)-polymerase (PARP) inhibitor sensitivity and genetic predisposition. In the Netherlands, BRCA1/2 testing changed to a tumor-first approach to efficiently identify both somatic and germline pathogenic variants in all patients. Here, we performed an in-depth...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.